Eosinophilic Esophagitis: Treatment with Oral Viscous Budesonide
Download in electronic PDF format for $75
Abstract: Eosinophilic esophagitis is a clinicopathologic disease isolated to the esophagus. It is caused by immunologic reactions to ingested and inhaled allergans. Symptoms include regurgitation, vomiting, pain, anorexia, and dysphagia. Endoscopy with biopsy is currently the only reliable diagnostic test for eosinophilic esophagitis. The disease should remit with treatments of dietary exclusion, topical corticosteroids, or both. Oral viscous budesonide is one of the promising options of topical corticosteroid to treat eosinophilic esophagitis. Since there are no commercial medicines of oral viscous budesonide, it is solely a compounded medication. This article briefly discusses the properties of the disease and covers a few compounding possibilities to oral viscous budesonide.
Related Keywords:
Eyal Zur, RPh, MBA, eosinophilic esophagitis, esophagus, immunologic reaction, allergens, dietary restrictions, topical administration, oral gel, viscous budesonide, topical corticosteroid, steroid gel, formulation
| Related Articles from IJPC |
Title/Author
(Click for Abstract / Details / Purchase) |
Issue/Page
View/Buy |
Eosinophilic Esophagitis: Treatment with Oral Viscous Budesonide
Zur Eyal
|
Jul/Aug 2012
Pg. 288-293
|
Oral Viscous Sucralfate Gel for Post-procedural Treatment of Barrett's Esophagus
Zur Eyal
|
Sep/Oct 2019
Pg. 376-381
|
Physical and Chemical Stability of Budesonide Mucoadhesive Oral Suspensions (MucoLox)
Ip Kendice, Carvalho Maria, Shan Ashley, Banov Daniel
|
Jul/Aug 2017
Pg. 322-329
|
Budesonide 0.0.25% Mucoadhesive Gel
Allen Loyd V Jr
|
Jul/Aug 2021
Pg. 323
|
Current Topical Treatments in Wound Healing - Part 1
Helmke Christopher D
|
Jul/Aug 2004
Pg. 269-274
|
Lidocaine Hydrochloride 2% Viscous Oral Topical Solution
Allen Loyd V Jr
|
May/Jun 2015
Pg. 243
|
Women's Oral Health: Is There a Hormonal Link?
Preckshot John
|
Jan/Feb 2004
Pg. 10-14
|
Budesonide 1-mg//10-mL Mucolox Oral Suspensions
Allen Loyd V Jr
|
Jul/Aug 2018
Pg. 317
|
Recurrent Aphthous Stomatitis: Topical Treatment with Minocycline and Other Evidence-based Agents
Zur Eyal
|
Nov/Dec 2012
Pg. 462-469
|
Physiochemical Compatibility of Nebulizable Drug Admixtures Containing Budesonide and Colistmethate or Hypertonic Saline
Klemmer Anja, Krämer Irene, Kamin Wolfgang
|
May/Jun 2013
Pg. 254-261
|
Sensitization Therapy for Warts
Kuntz Rachael
|
Jul/Aug 2003
Pg. 266-270
|
Infantile Hemangiomas, Part 2: Topical Treatment with Beta Blockers
Zur Eyal
|
Nov/Dec 2011
Pg. 458-463
|
Novel Approaches to Topical Psoriasis Therapy
Koyama Gregory, Liu Jenny, Scaffidi Alyse, Khazraee Maryam, Epstein Benjamin
|
Sep/Oct 2015
Pg. 357-365
|
Utilization of Compounded Medications in an Oral Medicine Practice
Stock Shannon, Rubino Katie, Woo Sook-Bon, Margolis Arthur, Thomas Irena, Aboalela Ali, Treister Nathaniel
|
Mar/Apr 2016
Pg. 155-158
|
Basics of Compounding for Raynaud's Disease
Glasnapp Andrew
|
Jul/Aug 2003
Pg. 288-291
|
Pediatric Compounding: Coloring Outside the Lines
Preckshot John
|
Jan/Feb 2001
Pg. 6-8
|
Topical Treatment of Cutaneous Leishmaniasis in Israel, Part 3
Zur Eyal
|
Sep/Oct 2019
Pg. 366-375
|
Topical Treatment of Cutaneous Leishmaniasis in Israel, Part 1
Zur Eyal
|
May/Jun 2019
Pg. 200-207
|
Topical Treatment of Cutaneous Leishmaniasis in Israel, Part 2
Zur Eyal
|
Jul/Aug 2019
Pg. 288-293
|
Case Report: Topical Gel for the Treatment of a Refractory Leg Ulcer
Israel Alan
|
May/Jun 2003
Pg. 176-178
|
| Return to Top |
